PMID- 25930239
OWN - NLM
STAT- MEDLINE
DCOM- 20160222
LR  - 20191210
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 93
DP  - 2015 Jun
TI  - Is the cellular uptake of respiratory aerosols delivered from different devices 
      equivalent?
PG  - 320-7
LID - S0939-6411(15)00191-5 [pii]
LID - 10.1016/j.ejpb.2015.04.012 [doi]
AB  - The study focuses on the application of a cell integrated modified Andersen 
      Cascade Impactor (ACI) as an in vitro lung model for the evaluation of aerosols' 
      behaviour of different formulation devices, containing the same active drug, 
      specifically nebuliser, pressurised metered dose inhaler (pMDI) and dry powder 
      inhaler (DPI). Deposition and transport profiles of the three different inhaled 
      salbutamol sulphate (SS) formulations with clinically relevant doses were 
      evaluated using a modified ACI coupled with the air interface Calu-3 bronchial 
      cell model. Reproducible amounts of SS were deposited on Snapwells for the 
      different formulations, with no significant difference in SS deposition found 
      between the standard ACI plate and modified plate. The transport of SS aerosols 
      produced from pMDI formulation had similar transport kinetics to nebulised SS but 
      significantly higher compared to the DPI, which could have led to the differences 
      in clinical outcomes. Furthermore, drug absorption of different inhaled 
      formulation devices of the same aerodynamic fraction was found not to be 
      equivalent due to their physical chemical properties upon aerosolisation. This 
      study has established an in vitro platform for the evaluation of the different 
      inhaled formulations in physiologically relevant pulmonary conditions.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Ong, Hui Xin
AU  - Ong HX
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia; Discipline of Pharmacology, Sydney Medical 
      School, University of Sydney, NSW 2000, Australia. Electronic address: 
      hong3117@uni.sydney.edu.au.
FAU - Traini, Daniela
AU  - Traini D
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia; Discipline of Pharmacology, Sydney Medical 
      School, University of Sydney, NSW 2000, Australia.
FAU - Loo, Ching-Yee
AU  - Loo CY
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia.
FAU - Sarkissian, Lala
AU  - Sarkissian L
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia; Discipline of Pharmacology, Sydney Medical 
      School, University of Sydney, NSW 2000, Australia.
FAU - Lauretani, Gianluca
AU  - Lauretani G
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia; Department of Chemical and Pharmaceutical 
      Sciences, University of Ferrara, Ferrara, Italy.
FAU - Scalia, Santo
AU  - Scalia S
AD  - Department of Chemical and Pharmaceutical Sciences, University of Ferrara, 
      Ferrara, Italy.
FAU - Young, Paul M
AU  - Young PM
AD  - Respiratory Technology, Woolcock Institute of Medical Research, The University of 
      Sydney, NSW 2037, Sydney, Australia; Discipline of Pharmacology, Sydney Medical 
      School, University of Sydney, NSW 2000, Australia.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Validation Study
DEP - 20150427
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Aerosols)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Powders)
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - Administration, Inhalation
MH  - Aerosols
MH  - Albuterol/*administration & dosage/chemistry/metabolism
MH  - Bronchodilator Agents/*administration & dosage/chemistry/metabolism
MH  - Cell Culture Techniques
MH  - Cell Line
MH  - Chemistry, Pharmaceutical
MH  - *Dry Powder Inhalers
MH  - Epithelial Cells/*metabolism
MH  - Equipment Design
MH  - Humans
MH  - *Metered Dose Inhalers
MH  - Particle Size
MH  - Powders
MH  - Reproducibility of Results
MH  - Respiratory Mucosa/*metabolism
MH  - Technology, Pharmaceutical/methods
OTO - NOTNLM
OT  - Andersen cascade impactor
OT  - Calu-3
OT  - DPI
OT  - Inhaled formulation
OT  - Nebuliser
OT  - Salbutamol
OT  - pMDI
EDAT- 2015/05/02 06:00
MHDA- 2016/02/24 06:00
CRDT- 2015/05/02 06:00
PHST- 2015/02/12 00:00 [received]
PHST- 2015/04/03 00:00 [revised]
PHST- 2015/04/21 00:00 [accepted]
PHST- 2015/05/02 06:00 [entrez]
PHST- 2015/05/02 06:00 [pubmed]
PHST- 2016/02/24 06:00 [medline]
AID - S0939-6411(15)00191-5 [pii]
AID - 10.1016/j.ejpb.2015.04.012 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2015 Jun;93:320-7. doi: 10.1016/j.ejpb.2015.04.012. Epub 
      2015 Apr 27.